Brazil study of 43K adults reveals GLP-1 blood pressure effects

A new analysis of more than 43,000 adults shows that GLP-1 drugs may lower blood pressure, and the effect is directly tied to weight loss. Researchers presented the findings at the European Congress on Obesity in May 2026.

The meta-analysis looked at 32 phase 3 clinical trials. The average participant was 54 years old, and about 59% had high blood pressure at the start of the study. Participants took GLP-1 medications for about 15 months on average.

The study found that for every 1% of body weight lost, participants saw a drop in their systolic blood pressure, the top number in a reading. The more weight someone lost, the more their blood pressure decreased. This link held true regardless of how long the study lasted, the person’s starting weight, sex, or whether they had diabetes.

Excess weight and high blood pressure are known to be connected. This analysis puts a number on that link for people taking GLP-1 drugs. A 2024 analysis of three large trials found that semaglutide, the active ingredient in Ozempic and Wegovy, lowered blood pressure more than a placebo. The results were similar even in people who already had high blood pressure. A separate 2024 review of 15 trials found the same blood pressure improvements alongside weight loss. A 2023 analysis of 61 trials found that semaglutide led to the greatest blood pressure reduction of any drug studied.

Researchers also noted that these drugs may lower blood pressure through other means, even without weight loss. The drugs may relax blood vessels, improve how the kidneys handle salt, and reduce stress signals in the body. This means GLP-1 drugs and newer medications that target multiple hormones at once may work through two pathways. One is tied to weight loss. The other acts directly on the heart and kidneys. This second pathway is still being studied, but it may explain why some patients see blood pressure benefits that seem larger than what their weight loss alone would suggest.

Obesity and high blood pressure often occur together and make each other worse. Clinical guidelines already recommend managing weight as a key way to lower blood pressure. For the 59% of trial participants with high blood pressure, the blood pressure drop was a meaningful result on its own. For people taking these drugs mainly for weight loss, the heart effects add important context.

The analysis has limits. It used data from trials, not from individual patients. The trials varied in their design and the people they included. Blood pressure was not the main focus of any of the trials. Some patients may have changed their blood pressure medications during the studies, which could have affected the results. Several trials are now underway to study these effects further, looking at how the drugs affect heart and blood vessel function, kidney health, and hormone pathways.

Despite these limits, the consistency of the findings across 32 trials and more than 43,000 people is hard to ignore. GLP-1 drugs are already changing how doctors think about weight. This analysis adds a new layer, showing they may also be useful for managing blood pressure. This is especially relevant for the many people who have both obesity and high blood pressure.